News Sentiment

HUMA sentiment intelligence

Humacyte Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 53 Balanced news tone 61 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 0.69 Week of 10 Jul 2026
Weighted tone 53/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

76/100 classification confidence.

Company focus 53

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-2.3% over one week, -34.2% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know

Market Reaction

Balanced read

60/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 76/100 classification
One-week reaction -2.3% Price reacting lower
Trend fit Trend inactive -34.2% over four weeks
Fair value -77.4% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 13
Neutral 39
Negative 9

Relevance

Why the article matched

Direct first
Direct company coverage 53
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 12
Stock Titan 11
TradingView 8
simplywall.st 7
Investing.com 4
TradingKey 4
The Manila Times 2
Investing.com South Africa 1

Event Lens

What the news is about

Classified themes
Market update 27
Earnings 25
Deals and strategy 4
Analyst action 3
Capital return 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 61
grafa.com Direct company coverage

Humacyte (NASDAQ:HUMA) reports positive Phase 3 V012 trial results

Humacyte (NASDAQ:HUMA) announced positive Phase 3 V012 trial results for its bioengineered blood vessel (ATEV), demonstrating superiority over traditional AV fistulas for women on dialysis. The ATEV showed a significant increase in catheter-free days and a lower infection rate. H

Tone
Positive 94/100
Event
Earnings
Published
15 Jun 2026 14:38
Source
grafa.com
Stock Titan Direct company coverage

Fresenius updates 6.8% Humacyte (HUMA) ownership stake disclosure

Fresenius Medical Care Holdings, Inc. and Fresenius Medical Care AG disclosed an updated beneficial ownership of 18,312,735 shares, representing 6.8% of Humacyte's outstanding common stock. This percentage decreased from 8.4% not due to share disposition by Fresenius, but solely

Tone
Neutral 50/100
Event
Deals and strategy
Published
15 Jun 2026 13:38
Source
Stock Titan
Stock Titan Direct company coverage

Bioengineered blood vessel helps women on dialysis avoid catheters longer

Humacyte's bioengineered blood vessel (ATEV) significantly outperformed the standard AV fistula in a Phase 3 study for women on dialysis, leading to more catheter-free days and fewer infections. The positive results support Humacyte's plan to file a supplemental Biologics License

Tone
Positive 73/100
Event
Earnings
Published
15 Jun 2026 11:38
Source
Stock Titan